EyePoint announced topline data from the LUGANO Phase 3 trial for DURAVYU in wet AMD. The primary endpoint was not achieved in the full dataset due to an asymmetric cohort of nine patients experiencing vision loss unrelated to wet AMD. However, an ad hoc analysis excluding this group showed non-inferiority versus aflibercept (p=0.0096). Key secondary endpoints were met, including a 42% reduction in treatment burden and superior supplement-free rates. The company plans to report LUCIA data in Q4 2026 and submit an NDA in H1 2027. EyePoint is a clinical-stage biopharmaceutical company developing therapeutics for retinal diseases.

EyePoint, Inc. reported second quarter 2026 financial results showing total net revenue of $0.5 million and a net loss of $94.5 million, or ($1.09) per share, compared to $5.3 million in revenue and a $59.4 million net loss in the prior year period. Operating expenses increased to $97.9 million from $67.6 million due to ongoing Phase 3 clinical trials for DURAVYU and manufacturing scale-up. The company holds $180 million in cash and investments, providing operational runway into the fourth quarter of 2027. Clinically, top-line data for the pivotal Phase 3 LUGANO wet AMD trial is expected in August 2026, with LUCIA following in Q4 2026; DME trials COMO and CAPRI are fully enrolled with topline data anticipated in Q4 2027. EyePoint, Inc. operates as a clinical-stage biopharmaceutical company developing innovative therapeutics for serious retinal diseases.

EyePoint, Inc. announced the completion of enrollment in two pivotal Phase 3 clinical trials, COMO and CAPRI, evaluating DURAVYU™ (vorolanib intravitreal insert) for diabetic macular edema (DME). The company enrolled over 480 participants across both global trials within five months, ahead of schedule. Topline data from these DME studies is anticipated in the fourth quarter of 2027. This milestone follows a Data Safety Monitoring Committee review that recommended continuing both the DME and wet AMD Phase 3 programs without protocol modifications. EyePoint, Inc. operates as a clinical-stage biopharmaceutical company developing innovative therapeutics for serious retinal diseases.

EyePoint, Inc. entered into a settlement agreement with the U.S. Department of Justice and other agencies to settle potential civil False Claims Act violations related to DEXYCU sales and marketing practices between 2019 and 2023. The company will pay a settlement amount of $4,678,981.86 plus 4.25% interest, along with $166,500 in attorney's fees. Additionally, the company entered into a five-year Corporate Integrity Agreement with OIG-HHS to maintain compliance oversight. EyePoint, Inc. is a pharmaceutical company that commercializes healthcare products.

At its 2026 Annual Meeting of Stockholders on June 18, 2026, EyePoint, Inc. stockholders approved an amendment to the 2023 Long-Term Incentive Plan, increasing the number of authorized common shares for issuance by 4,900,000. Stockholders also elected eight directors, ratified the appointment of Deloitte & Touche LLP as the independent auditor for fiscal year 2026, and approved named executive officer compensation on a non-binding advisory basis. The company operates in the biotechnology industry and develops ophthalmic pharmaceuticals.